BioReliance Corporation Announces Agreement with Barr Pharmaceuticals, Inc. to Supply Bulk Virus for the Manufacture of Adenovirus Vaccine for the U.S. Department of Defense
Published: Jan 06, 2009
ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that it has been contracted by Barr Pharmaceuticals, Inc. to supply bulk adenovirus for the manufacture of Duramed Pharmaceuticals, Inc.’s Adenovirus Types 4 and 7 Live Oral Vaccines. Duramed, a subsidiary of Barr Pharmaceuticals, announced on December 11, 2008, that the U.S. Food and Drug Administration has accepted for review Duramed’s Biologics License Application for the vaccines. The vaccines will be used by the U.S. Department of Defense for administration to military personnel.